Get the Stockscreener App
752.60
0.73%
-2.91
Regeneron Pharmaceuticals Inc stock is traded at $752.60, with a volume of 25,616.
It is down -0.73% in the last 24 hours and up +0.56% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$755.51
Open:
$758.67
24h Volume:
25,616
Relative Volume:
0.03
Market Cap:
$79.46B
Revenue:
$14.34B
Net Income/Loss:
$4.50B
P/E Ratio:
18.11
EPS:
41.5626
Net Cash Flow:
$3.77B
1W Performance:
-3.30%
1M Performance:
+0.56%
6M Performance:
+30.11%
1Y Performance:
+34.42%
1-Day Range:
$748.03
$760.58
1-Week Range:
$737.34
$772.45
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
VRTX
Vertex Pharmaceuticals Inc
|
441.14 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
842.62 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
335.80 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.32 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Inside Biotech: Telix rally meets reality check as $600m raise tempers Regeneron-driven surge - Proactive financial news
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Boosts Cancer Pipeline Through Telix Collaboration - Yahoo Finance
A $2.1 Billion Radiopharmaceutical Collaboration, Explained - PharmTech.com
Third View Private Wealth Boosts Regeneron Pharmaceuticals Stake - National Today
Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report - Barchart.com
Third View Private Wealth LLC Acquires Shares of 7,149 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Telix Pharmaceuticals (ASX:TLX) Is Up 13.8% After Regeneron Radiopharma Alliance Announcement And What’s Next - Yahoo Finance
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance
Is It Too Late To Consider Regeneron (REGN) After Its 31% One‑Year Rally? - simplywall.st
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - WebWire
Regeneron (REGN) Partners with Telix Pharmaceuticals for Innovat - GuruFocus
Regeneron Pharmaceuticals Inc stock (US7739031091): Is Eylea dominance still the real growth engine? - AD HOC NEWS
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Regeneron Pharmaceuticals (REGN) Partners with Telix for Radioph - GuruFocus
Regeneron and Telix reveal radiopharm collab - The Pharma Letter
Regeneron enters radiopharma space via Telix deal - BioWorld News
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals - Pharmaceutical Executive
Regeneron, Telix Enter Strategic Radiopharma Collaboration - Contract Pharma
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria - Yahoo Finance Singapore
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026 - FinancialContent
Regeneron enters radiopharma ring with up to $4.3B Telix alliance - BioSpace
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor ProgramsRegeneron Pharmaceuticals (NASDAQ:R - Benzinga
Regeneron, Sanofi Get Expanded Europe OK for Dupixent in Younger Children With CSU - National Today
Regeneron (REGN) Partners with Telix Pharmaceuticals - GuruFocus
H.C. Wainwright reiterates Telix stock rating on Regeneron deal - Investing.com
Regeneron, Telix partner on radiopharmaceutical cancer therapies By Investing.com - Investing.com Canada
Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies - Yahoo Finance
Regeneron, Telix partner on radiopharmaceutical cancer therapies - Investing.com
Regeneron and Telix Announce Strategic Radiopharma Collaboration - The Manila Times
Regeneron taps Telix in $40M push for next-generation cancer drugs - Stock Titan
Sumitomo Mitsui Trust Group Inc. Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Burney Co. Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - National Today
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) - National Today
Sanofi (SNY) and Regeneron (REGN) Gain EU Approval for Dupixent in Young Children - GuruFocus
Sanofi, Regeneron’s Dupixent approved in EU for young children with chronic urticaria (SNY:NASDAQ) - Seeking Alpha
Dupixent Approved in EU for Treating Children with CSU - Intellectia AI
Regeneron and Sanofi Announce European Commission Approval of Dupixent for Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years - Quiver Quantitative
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - The Manila Times
Australia's Telix Pharma announces strategic radiopharma collaboration worth $535 M with Regeneron - BioSpectrum Asia
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - MSN
Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal - The Motley Fool Australia
Telix and Regeneron Announce Strategic Radiopharma Collaboration - PR Newswire
Jim Cramer on Regeneron (REGN): “I Think The Stock’s Breaking Out Here” - Insider Monkey
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit - GuruFocus
Robeco Institutional Asset Management Boosts Regeneron Pharmaceuticals Stake - National Today
Robeco Institutional Asset Management B.V. Purchases 140,966 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How Investors May Respond To Regeneron (REGN) Extending EYLEA HD Dosing Intervals To 20 Weeks - simplywall.st
Should FDA Approval of Extended EYLEA HD Dosing Flexibility Require Action From Regeneron Pharmaceuticals (REGN) Investors? - Yahoo Finance
Regeneron Pharmaceuticals, Inc. $REGN Stake Raised by Bar Harbor Wealth Management - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):